BioInvent (BOVNF): Positive Results From the BI-505 Phase I Study in Multiple Myeloma
1/24/2013 8:51:53 AM
LUND, Sweden--(BUSINESS WIRE)--BioInvent International (OMXS:BINV) announced today the first results from the BI-505 phase I study in patients with multiple myeloma. The study has reached a final stage and the preliminary analysis shows that BI-505 has an advantageous safety profile. In cohorts where extended therapy was available, 24 % of the patients had stable disease for at least two months, indicating effect of BI-505. The final conclusions of the study will be available at a later time-point. The optimal dose has been defined according to the study protocol and will be used in the next clinical trial which is approved by the health authorities.